Stephen Mandel’s Exact Sciences EXAS Stock Holding History

Stephen Mandel’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,298,001	Closed	-$52.3M	–	31
2018 Q1	$52.3M	Buy	+1,298,001	New	+$63.3M	0.27%	29

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Stephen Mandel's EXAS Position: Q2 2018 in Review

Stephen Mandel sold out of Exact Sciences (EXAS) in Q2 2018, closing a stake of 1,298,001 shares — an estimated $52.3M sold.

Stephen Mandel first reported a position in EXAS in Q1 2018 and held it in 1 quarter. The position peaked at $52.3M in Q1 2018. 349 funds tracked by Wall St. Rank hold EXAS as of Q2 2018.

Stephen Mandel reported no remaining Exact Sciences position as of Q2 2018 after selling out during the quarter.
Stephen Mandel sold 1,298,001 Exact Sciences shares in Q2 2018, an estimated $52.3M.
Stephen Mandel first reported a position in Exact Sciences in Q1 2018 and held it in 1 quarter.
Stephen Mandel's Exact Sciences position peaked at $52.3M in Q1 2018.
349 funds tracked by Wall St. Rank held Exact Sciences as of Q2 2018.

Based on Lone Pine Capital's 13F filing for Q2 2018, filed 14 Aug 2018.